Enovis (NYSE:ENOV) Trading 10.1% Higher After Strong Earnings

Shares of Enovis Corporation (NYSE:ENOV) traded up 10.1% on Thursday following a better than expected earnings announcement. The company traded as high as $27.73 and last traded at $27.3560. 865,582 shares were traded during trading, a decline of 14% from the average session volume of 1,008,345 shares. The stock had previously closed at $24.85.

The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the prior year, the firm earned $0.81 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS.

Wall Street Analyst Weigh In

ENOV has been the subject of several research reports. William Blair initiated coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. BTIG Research increased their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company raised shares of Enovis to a “strong-buy” rating in a research report on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $47.43.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert bought 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the transaction, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 5,000 shares of company stock valued at $121,983 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Annis Gardner Whiting Capital Advisors LLC grew its position in Enovis by 468,400.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company’s stock valued at $107,000 after purchasing an additional 4,684 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after acquiring an additional 287,687 shares during the last quarter. Calamos Wealth Management LLC acquired a new stake in Enovis in the first quarter valued at $290,000. Principal Financial Group Inc. lifted its stake in Enovis by 2.0% in the first quarter. Principal Financial Group Inc. now owns 277,973 shares of the company’s stock valued at $6,324,000 after acquiring an additional 5,409 shares during the last quarter. Finally, Fifth Third Bancorp lifted its stake in Enovis by 50,442.8% in the first quarter. Fifth Third Bancorp now owns 83,901 shares of the company’s stock valued at $1,909,000 after acquiring an additional 83,735 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Trading Up 9.8%

The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -1.32 and a beta of 1.41. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The business’s 50 day simple moving average is $23.78 and its 200 day simple moving average is $25.83.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.